Role of Methotrexate in the Treatment of Chronic Cholestatic Disorders

O'Dell, 2005, Methotrexate, leflunomide, and combination therapies, 996 Lipsky, 2000, Infliximab and methotrexate in the treatment of rheumatoid arthritis, N Engl J Med, 26, 27 Heydendael, 2003, Methotrexate versus cyclosporine in moderate to severe chronic plaque psoriasis, N Engl J Med, 349, 658, 10.1056/NEJMoa021359 Alfadhi, 2003, Methotrexate for the induction of remission of refractory Crohn's disease, Cochrane Database Syst Rev, 1 Feagan, 1995, Methotrexate for the treatment of Crohn's disease, N Engl J Med, 332, 292, 10.1056/NEJM199502023320503 Cronstein, 1997, The mechanism of action of methotrexate, Rheum Dis Clin North Am, 23, 739, 10.1016/S0889-857X(05)70358-6 Barrera, 1995, Effect of methotrexate alone or in combination with suphasalazine on the production and circulating concentrations of cytokines and their antagonists: longitudinal evaluation in patients with rheumatoid arthritis, Br J Rheumatol, 34, 747, 10.1093/rheumatology/34.8.747 Pincus, 2003, Methotrexate as the “anchor drug” for the treatment of early rheumatoid arthritis, Clin Exp Rheumatol, 21, S179 Johnston, 2005, The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules, Clin Immunol, 114, 154, 10.1016/j.clim.2004.09.001 Rudwaleit, 2000, Response to methotrexate in early rheumatoid arthritis is associated with a decrease in T cell derived tumour necrosis factor-alpha, increase of interleukin 10 and predicted by the initial concentration of interleukin 4, Ann Rheum Dis, 59, 311, 10.1136/ard.59.4.311 Kraan, 2004, Differential effects of leflunomide and methotrexate on cytokine production in rheumatoid arthritis (rheumatic disease research), Ann Rheum Dis, 63, 1056, 10.1136/ard.2003.014738 Barsky, 2007, The expanding family of interleukin-1 cytokines and their role in destructive inflammatory disorders, Clin Experim Immunol, 149, 217, 10.1111/j.1365-2249.2007.03441.x Zwerina, 2007, TNF-induced structural joint damage is mediated by IL-1, Proc Natl Acad Sci U S A, 104, 11742, 10.1073/pnas.0610812104 Neuman, 2002, Tumor necrosis factor-α and transforming growth factor-β reflect severity of liver damage in primary biliary cirrhosis, J Gastroenterol Hepatol, 17, 196, 10.1046/j.1440-1746.2002.02672.x Donaldson, 2001, HLA and cirrhosis: associations with disease progression and disease susceptibility, GUT, 48, 397, 10.1136/gut.48.3.397 Miller, 1986, Methotrexate inhibits IL-1 activity, Arthritis Rheum, 29, S86 Miller, 1995, Synthesis of interleukin-1β in primary biliary cirrhosis: relationship to treatment with methotrexate or colchicines and disease progression, Hepatology, 22, 518 La Montagna, 2006, Safety of methotrexate in rheumatoid arthritis: a retrospective cohort study in clinical practice, Rheumatism, 58, 261 Tilling, 2006, Methotrexate and hepatic toxicity in rheumatoid arthritis and psoriatic arthritis, Clin Drug Investig, 26, 55, 10.2165/00044011-200626020-00001 Suarez-Almazor, 1997, Methotrexate for the treatment of rheumatoid arthritis, Cochrane Database Syst Rev, 2 Whiting-O'Keefe, 1991, Methotrexate and histologic hepatic abnormalities: a meta-analysis, Am J Med, 90, 711, 10.1016/S0002-9343(05)80060-9 Kaplan, 1996, Primary biliary cirrhosis, N Engl J Med, 335, 1570, 10.1056/NEJM199611213352107 Tanaka, 2001, Genetic and familial considerations of primary biliary cirrhosis, Am J Gastroenterol, 95, 8, 10.1111/j.1572-0241.2001.03446.x Donaldson, 2001, HLA and interleukin 1 gene polymorphisms in primary biliary cirrhosis: associations with disease progression and disease susceptibility, Gut, 48, 397, 10.1136/gut.48.3.397 Berg, 1997, Cytokines in primary biliary cirrhosis, Semin Liver Dis, 17, 115, 10.1055/s-2007-1007189 Jones, 1990, Tumor necrosis factor, cholestatic jaundice and chronic liver disease, Gut, 31, 938, 10.1136/gut.31.8.938 Pelli, 2007, Soluble apoptosis molecules in primary biliary cirrhosis: analysis and commitment of the Fas and tumor necrosis factor-related apoptosis-inducing ligand systems in comparison with chronic hepatits C, Clin Exp Immunol, 148, 85, 10.1111/j.1365-2249.2006.03293.x Mullin, 1996, mRNA expression in the liver of patients with primary biliary cirrhosis and chronic hepatitis B, Clin Exp Immunol, 105, 254, 10.1046/j.1365-2249.1996.d01-759.x Harada, 1997, In situ nucleic acid hybridization of cytokines in primary biliary cirrhosis: predominance of the Th1 subset, Hepatology, 25, 791, 10.1002/hep.510250402 Morland, 1997, Promotyion of leukocytye transendothelial cell migration by chemokines derived from human biliary epithelial cells in vitro, Proc Assoc Am Physicians, 109, 372 Bjorkland, 1991, Blood and liver infiltrating lymphocytes in primary biliary cirrhosis: Increased in activated T and natural killer cells and recruitment of primed memory T cells, Hepatology, 13, 1106 Yeaman, 2000, Autoreactive responses to pyruvate dehydrogenase complex in the pathogenesis of primary biliary cirrhosis, Immunol Rev, 174, 238, 10.1034/j.1600-0528.2002.00021h.x Isse, 2006, Characterization of biliary intra-epithelial lymphocytes at different anatomic levels of intrahepatic bile ducts under normal and pathologic conditions: numbers of CD4 + CD28- intra-epitheliual lymphocytes are increased in primary biliary cirrhosis, Pathol Int, 56, 17, 10.1111/j.1440-1827.2006.01913.x Furtwaengler, 2001, Apoptotic pathways in primary biliary cirrhosis and autoimmune hepatitis, Liver, 21, 272, 10.1034/j.1600-0676.2001.021004272.x Kita, 2002, Quantitation and phenotypic analysis of natural killer T cells in primary biliary cirrhosis using a human CD1d tetramer, Gastroenterology, 123, 1031, 10.1053/gast.2002.36020 Lan, 2006, Liver targeted and peripheral blood alterations of regulatory T cells in primary biliary cirrhosis, Hepatology, 43, 729, 10.1002/hep.21123 Wong, 2007, Heath-related quality of life in Chinese patients with primary biliary cirrhosis, J Gastroenterol Hepatol Heathcote, 2000, AASLD practice guidelines. Management of primary biliary cirrhosis, Hepatology, 31, 1005, 10.1053/he.2000.5984 Pares, 2006, Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid, Gastro, 130, 715, 10.1053/j.gastro.2005.12.029 Setchell, 1997, Bile acid concentrations in human and rat liver tissue and in hepatocyte nuclei, Gastro, 112, 226, 10.1016/S0016-5085(97)70239-7 Capechot, 2000, The effect of ursodeoxycholic acid on liver fibrosis in primary biliary cirrhosis, Hepatology, 32, 1196, 10.1053/jhep.2000.20240 Jackson, 2007, Influence of ursodeoxycholic acid on the mortality and malignancy associated with primary biliary cirrhosis: a population-based cohort study, Hepatology, 10.1002/hep.21795 Kaplan, 1995, Sustained remission of primary biliary cirrhosis with methotrexate, Gastro, S108, A1094 Kaplan, 1991, Treatmentof primary biliary cirrhosis with low-dose weekly methotrexate, Gastro, 101, 1332, 10.1016/0016-5085(91)90085-Y Bonis, 1999, Methotrexate improves biochemical test in patients with primary biliary cirrhosis who respond incompletely to ursodeoxycholic acid, Gastro, 117, 395, 10.1053/gast.1999.0029900395 Kaplan, 2004, A randomized controlled trial of colchicines plus ursodiol versus methotrexate plus ursodiol in primary biliary cirrhosis: ten year results, Hepatology, 39, 915, 10.1002/hep.20103 Lindor, 1995, The combination of ursodeoxycholic acid and methotrexate for patients with primary biliary cirrhosis: the result of a pilot study, Hepatology, 22, 1158 Van Steenbergen, 1996, Combined treatment with methotrexate and ursodeoxycholic acid in non-cirrhotic primary biliary cirrhosis, Acta Clin Belg, 51, 8, 10.1080/17843286.1996.11718480 Copaci, 2001, Ursodeoxycholic acid and methotrexate for primary biliary cirrhosis, J Hepatol, 34, 59, 10.1016/S0168-8278(01)80199-9 Gonzalez-Koch, 1997, The combination of ursodeoxycholic acid and methotrexate for primary biliary cirrhosis is not better than ursodeoxycholic acid alone, J Hepatol, 27, 143, 10.1016/S0168-8278(97)80294-2 Combes, 2005, Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis, Hepatology, 42, 1184, 10.1002/hep.20897 Bach, 2003, Methotrexate therapy for primary biliary cirrhosis, Am J Gastroenterol, 98, 187, 10.1111/j.1572-0241.2003.07173.x Poupon, 2004, Trials in primary biliary cirrhosis: need for the right drugs at the right time, Hepatology, 39, 900, 10.1002/hep.20188 Hendrickse, 1999, Low-dose methotrexate is ineffective in primary biliary cirrhosis: long-term results of a placebo controlled trial, Gastro, 117, 400, 10.1053/gast.1999.0029900400 Gong, 2005, Methotrexate for primary biliary cirrhosis, Cochrane Database Syst Rev, 3 Huet, 2000, Impact of fatigue on the quality of life of patients with primary biliary cirrhosis, Am J Gastroenterol, 95, 760, 10.1111/j.1572-0241.2000.01857.x Goulis, 1999, Randomized controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis, Lancet, 354, 1053, 10.1016/S0140-6736(98)11293-X Wolfhagen, 1997, Oral natrexone treatment for cholestastic pruritus: a double blind, placebo controlled study, Gastroenterology, 113, 1264, 10.1053/gast.1997.v113.pm9322521 Ghent, 1988, Treatment of pruritus in primary biliary cirrhosis with rifampin, Gastroenterology, 94, 488, 10.1016/0016-5085(88)90442-8 Bergassa, 2004, The treatment of the pruritus of cholestasis, Curr Treat Options Gastroenterol, 7, 501, 10.1007/s11938-004-0009-1 Maddrey, 1998, Liver transplantation: an overview, Hepatology, 8, 948, 10.1002/hep.1840080440 Jones, 2006, Four year follow-up of fatigue in a geographically defined primary biliary cirrhosis patient cohort, Gut, 55, 536, 10.1136/gut.2005.080317 Swain, 2006, Fatigue in liver disease: pathophysiology and clinical management, Can J Gastroenterol, 20, 181, 10.1155/2006/624832 Milkiewicz, 2004, Fatigue in chronic cholestasis, Gut, 53, 475, 10.1136/gut.2003.025155 Bergasa, 1996, Pilot study of low dose oral methotrexate treatment for primary biliary cirrhosis, Am J Gastroenterol, 91, 295 Buscher, 1993, Positive responses to methotrexate and ursodeoxycholic acid in patients with primary biliary cirrhosis responding insufficiently to ursodeoxycholic acid alone, J Hepatol, 18, 9, 10.1016/S0168-8278(05)80004-2 Babatin, 2006, Methotrexate therapy for the symptomatic treatment of primary biliary cirrhosis patients, who are biochemical incomplete responders to ursodeoxycholic acid therapy, Aliment Pharmacol Ther, 24, 813, 10.1111/j.1365-2036.2006.03048.x Swain, 1998, Augmented interleukin-1β–induced depression of locomoter activity in cholestatic rats, Hepatology, 28, 1561, 10.1002/hep.510280616 Swain, 2003, Molecular pathophysiology of fatigue and pruritus Davis, 2000, Methotrexate as a steroid sparing agent for asthma in adults, Cochrane Database Syst Rev, 2 Bambha, 2003, Incidence, clinical spectrum and outcome of primary sclerosing cholangitis in a United States community, Gastro, 125, 1364, 10.1016/j.gastro.2003.07.011 O'Mahony, 2006, Etiopathogenesis of primary sclerosing cholangitis, Semin Liver Dis, 26, 3, 10.1055/s-2006-933559 Bo, 2001, Tumor necrosis factor-alpha impairs function of liver derived T lymphocytes and natural killer cells in patients with primary sclerosing cholangitis, Gut, 49, 131, 10.1136/gut.49.1.131 Aoki, 2005, The immunobiology of primary sclerosing cholangitis, Autoimmun Rev, 4, 137, 10.1016/j.autrev.2004.09.003 LaRusso, 2006, Primary sclerosing cholangitis: summary of a workshop, Hepatology, 44, 746, 10.1002/hep.21337 Michell, 2001, A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis, Gastro, 121, 900, 10.1053/gast.2001.27965 Harnois, 2001, High-dose ursodeoxycholic acid as therapy for primary sclerosing cholagitis, Am J Gastroenterol, 96, 1558, 10.1111/j.1572-0241.2001.03777.x Olsson, 2005, High dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5 year, multicenter, randomized controlled trial, Gastro, 129, 1464, 10.1053/j.gastro.2005.08.017 Lindor, 1991, The combination of prednisone and colchicines in patients with primary sclerosing cholangitis, Am J Gastroenterol, 86, 57 Talkwalkar, 2005, Mycophenylate mofetil for the treatment of primary sclerosing cholangitis, Am J Gastroenterol, 100, 308, 10.1111/j.1572-0241.2005.40484.x Olsson, 1995, Colchicine treatment of primary sclerosing cholangitis, Gastro, 108, 1199, 10.1016/0016-5085(95)90220-1 Van Thie, 1995, Tacrolimus, a treatment for primary sclerosing cholangitis: results of an open-label preliminary trial, Am J Gastroenterol, 90, 455 Kaplan, 1987, Primary sclerosing cholangitis and low-dose oral pulse methotrexate therapy. Clinical and histologic response, Ann Intern Med, 106, 231, 10.7326/0003-4819-106-2-231 Knox, 1994, A double-blind controlled trial of oral-pulse methotrexate therapy in the treatment of primary sclerosing cholangitis, Gastro, 106, 494, 10.1016/0016-5085(94)90610-6 Lindor, 1996, Ursodeoxycholic acid and methotrexate for primary sclerosing cholangitis: a pilot study, Am J Gastroenterol, 91, 511 Duerksen, 1995, Pneumocytis carinii pneumonia complicating methotrexate treatment of primary sclerosing cholangitis, Am J Gastroenterol, 90, 1886